Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Mangoceuticals (MGRX) EBIAT (2023 - 2025)

Mangoceuticals' EBIAT history spans 3 years, with the latest figure at -$2.8 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 42.12% to -$2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.6 million, a 137.1% decrease, with the full-year FY2025 number at -$20.6 million, down 137.11% from a year prior.
  • EBIAT hit -$2.8 million in Q4 2025 for Mangoceuticals, up from -$7.6 million in the prior quarter.
  • Over the last five years, EBIAT for MGRX hit a ceiling of -$1.8 million in Q3 2023 and a floor of -$7.6 million in Q3 2025.
  • Historically, EBIAT has averaged -$3.2 million across 3 years, with a median of -$2.5 million in 2023.
  • Biggest five-year swings in EBIAT: increased 24.13% in 2024 and later tumbled 281.08% in 2025.
  • Tracing MGRX's EBIAT over 3 years: stood at -$2.6 million in 2023, then grew by 24.13% to -$1.9 million in 2024, then crashed by 42.12% to -$2.8 million in 2025.
  • Business Quant data shows EBIAT for MGRX at -$2.8 million in Q4 2025, -$7.6 million in Q3 2025, and -$5.4 million in Q2 2025.